Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

TOPOL SMOKER's MOUTHWASH SELL-IN CONTRIBUTES TO $3 MIL. INCREASE IN JEFFREY MARTIN

Executive Summary

TOPOL SMOKER's MOUTHWASH SELL-IN CONTRIBUTES TO $3 MIL. INCREASE IN JEFFREY MARTIN revenues for the fourth quarter of the fiscal year ended July 31. Commenting on a fourth quarter increase in sales from $12.3 mil. to $15.8 mil., Jeffrey Martin said: "The national sell-in ]of Topol Smoker's Mouthwash[, which began in June, met with very good trade acceptance. The new mouthwash contributed to the quarterly growth in revenues over the corresponding fourth quarter last year." Net income for the fourth quarter dropped 83.3% to $134,000 compared with $804,000 reported for the fourth quarter of 1984. The company explained that "heavy advertising expenses. . . as well as moderate promotional expenses associated with the introduction of the new mouthwash, cut deeply into earnings." For the year, Jeffrey Martin revenues increased 12% to $65.6 mil., while net income decreased 29.4% to $4 mil. Commenting on fiscal 1985 results, Jeffrey Martin Chairman Martin Himmel noted that "the addition of Lavoris ]acquired in July 1984[ and solid performances by Doan's pills and Ayds appetite suppressant candy offset a sales decline in Topol smoker's toothpolish" and contributed to a "return to solid growth in revenues." Martin noted that like the fourth quarter net income, year end results were affected by "media expenditures." Himmel said that Jeffrey Martin "spent heavily on advertising to support the long-term health of our brands, particularly to re-establish Lavoris as a leader in the mouthwash category."

Latest Headlines
See All
UsernamePublicRestriction

Register

PS008954

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel